Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about OMER, unsubscribe in one click. Privacy
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Narsoplimab (OMS721) FDA approved Dec 2025 · Yartemlea |
IgA Nephropathy | Phase 3 · NCT03608033 | Terminated |
| Phenylephrine And Ketorolac | Cataract | Phase 4 · NCT03864133 | Completed |
| Phenylephrine 1.0%/ Ketorolac 0.3% | Pain Reduction | Phase 4 · NCT04829799 | Withdrawn |
| 1% preservative-free lidocaine | Pain Reduction | Phase 4 · NCT04829799 | Withdrawn |
| OMS103HP | Knee Injuries | Phase 3 · NCT00226759 | Completed |
| OMS103HP-S | Meniscal Tear | Phase 3 · NCT01406561 | Completed |
| Phenylephrine HCl | Unilateral Cataract Extraction | Phase 3 · NCT02132312 | Completed |
| OMS302 | Unilateral Cataract Extraction | Phase 3 · NCT02132312 | Completed |
| Part 2 OMS302 | Intraocular Lens Replacement | Phase 3 · NCT02093689 | Terminated |
| Part 1 OMS302 | Intraocular Lens Replacement | Phase 3 · NCT02093689 | Terminated |
| OMS302-PE | Cataract Extraction | Phase 1/2 · NCT00721695 | Completed |
| OMS906 study drug | C3 Glomerulopathy | Phase 2 · NCT06209736 | Recruiting |
| Zaltenibart | Paroxysmal Nocturnal Hemoglobinuria | Phase 2 · NCT05972967 | Completed |
| OMS643762 | Schizophrenia | Phase 2 · NCT01952132 | Completed |
| OMS302 Mydriatic Solution | Cataract | Phase 2 · NCT01193127 | Completed |
| OMS302 Anti-inflammatory Solution | Cataract | Phase 2 · NCT01193127 | Completed |
Also used in these trials (approved or third-party drugs, not OMER's own candidates): Pioglitazone, Balanced Salt.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
OMER holds $132M in cash and short-term investments (as of Jun 30, 2026) and burns about $5.2M/quarter from operations, an estimated runway of 76.4 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 25 · Moderate
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when OMER files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| BlackRock, Inc. | Institution (13G, 5%+) | 5,961,792 | 8.24% | 2026-06-30 |
| Ingalls & Snyder LLC | Institution (13F) | 3,659,523 | 5.06% | 2026-06-30 |
| UBS Group AG | Institution (13F) | 3,148,384 | 4.35% | 2026-06-30 |
| Vanguard Capital Management LLC | Institution (13F) | 3,072,050 | 4.24% | 2026-06-30 |
| State Street Corporation | Institution (13F) | 2,319,906 | 3.20% | 2026-06-30 |
| Geode Capital Management, LLC | Institution (13F) | 1,914,460 | 2.64% | 2026-06-30 |
| Gregory A MD Demopulos Chairman, CEO & President, Director · +1.87M options |
Insider | 1,893,253 | 2.62% | 2026-02-18 |
| Stifel Financial Corporation | Institution (13F) | 1,836,925 | 2.54% | 2026-06-30 |
| Vanguard Portfolio Management LLC | Institution (13F) | 962,828 | 1.33% | 2026-06-30 |
| Invesco Ltd. | Institution (13F) | 751,771 | 1.04% | 2026-06-30 |
| Northern Trust Corporation | Institution (13F) | 727,348 | 1.00% | 2026-06-30 |
| Rock Springs Capital Management, LP | Institution (13F) | 718,499 | 0.99% | 2026-06-30 |
Share count 72,388,316 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-06-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.
| Trade date | Insider | Transaction | Shares | Price | Owned after |
|---|---|---|---|---|---|
| 2026-09-23 filed 2026-09-24 |
Borges David J. |
Sale (S) | 10,000 | $20.95 | 0 |
| 2026-09-23 filed 2026-09-24 |
Borges David J. |
Option exercise (M) | 10,000 | $15.58 | 10,000 |
| 2026-09-23 filed 2026-09-24 |
Borges David J. |
Option exercise (M) | 10,000 | – | – |
| 2026-09-22 filed 2026-09-24 |
Borges David J. |
Option exercise (M) | 5,000 | – | – |
| 2026-09-22 filed 2026-09-24 |
Borges David J. |
Option exercise (M) | 5,000 | – | – |
Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.
| Date | Drug | Type | Run-up 30d | Decision 1d | After 5d |
|---|---|---|---|---|---|
| 2025-05-06 | Narsoplimab | BLA | -7.5% | -6.9% | -44.2% |
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for OMER and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →